IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

# Gastro-Retentive Mucoadhesive Microballoons for Vonoprazan Fumarate: Literature-Based Review and Translational Development Framework

**Arti G. Samse*[1], Dr. Ravi U. Kurhade[2], Dr. Pratapsinh V. Kachave[3], Mr. Rushikesh S. Sarde[4], Mr. Nishinandan M. Shinde[5]**

[1]M. Pharm Final Year Student, Department of Pharmacology MDA School of Pharmacy, Kolpa, Latur, Maharashtra
[2]Principal, Department of Pharmaceutics MDA School of Pharmacy, Kolpa, Latur, Maharashtra
[3]Professor, Department of Pharmacology MDA School of Pharmacy, Kolpa, Latur, Maharashtra
[4]Assistant Professor, Department of Pharma Chemistry MDA School of Pharmacy, Kolpa, Latur, Maharashtra
[5]Assistant Professor, Department of Pharmaceutics MDA School of Pharmacy, Kolpa, Latur, Maharashtra
Corresponding Author: Arti G. Samse
samsearti@gmail.com

**Abstract:** *Vonoprazan fumarate is an acid-stable potassium-competitive acid blocker with rapid and sustained gastric acid suppression. Interest in gastro-retentive and mucoadhesive delivery arises from the possibility of controlling gastric drug release, but the literature requires careful interpretation. This review integrates evidence from five domains: peptic ulcer disease and acid suppression, vonoprazan pharmacology, gastro-retentive floating systems, mucoadhesive polymers, and Quality-by-Design with analytical validation, dissolution modelling and stability. The review shows that hollow microballoons can be prepared as low-density multiparticulates and that mucoadhesive polymers may provide temporary mucosal contact. However, in-vitro floating and ex-vivo adhesion are formulation attributes, not direct evidence of human gastric residence or clinical superiority. A development framework is proposed that connects drug properties, polymer selection, emulsion solvent diffusion-evaporation, critical quality attributes, Box-Behnken optimization, analytical controls and stability. The review concludes that the vonoprazan microballoon concept is scientifically testable, but final claims must be limited to the evidence generated.*

**Keywords:** vonoprazan; potassium-competitive acid blocker; gastro-retentive delivery; floating microballoons; mucoadhesion; Quality by Design; stability

## I. INTRODUCTION

Gastro-retentive drug delivery systems are designed to increase residence of a dosage form in the stomach or proximal gastrointestinal region. They include floating, high-density, expandable, raft-forming, magnetic and mucoadhesive systems. Their potential value depends on the drug, formulation design and gastric physiology; therefore, retention should not be assumed from dosage-form type alone [20-25].

Vonoprazan fumarate is a strong acid suppressant with a mechanism distinct from classical proton-pump inhibitors. It is pharmacologically relevant to acid-related disorders and H. pylori eradication regimens, but clinical utility of the drug does not automatically translate into clinical superiority of a modified-release carrier. The formulation question is whether the active can be incorporated reproducibly into a dosage form with controlled release, low apparent density, temporary mucosal interaction and acceptable stability [6-19].

The purpose of this review is to synthesize the literature most relevant to developing vonoprazan fumarate microballoons. The review emphasizes evidence boundaries, because many formulation manuscripts overstate the

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

meaning of static flotation tests, ex-vivo adhesion or release duration. A balanced review should define what in-vitro and ex-vivo data can show and what they cannot show.




*Figure 1. Evidence domains integrated in the review.*

## II. LITERATURE-SEARCH FRAMEWORK

The evidence base was organized into five linked domains: peptic ulcer disease and acid suppression; vonoprazan pharmacology and clinical evidence; gastro-retentive and floating systems; mucoadhesion and polymer selection; and QbD, analytical validation, release modelling and stability. Unverified placeholder records should be excluded, and every retained source should be traceable to a full citation.

*Table 1. Review domains and inclusion logic.*

| Domain | Evidence included | Reason for inclusion |
|---|---|---|
| Peptic ulcer disease | Disease mechanism, H. pylori, NSAID risk and acid suppression | Defines clinical context and claim boundary |
| Vonoprazan | Pharmacology, acid suppression, clinical/regulatory evidence | Supports drug selection |
| Floating systems | Gastro-retentive principles, hollow microballoons, physiological limits | Supports dosage-form concept |
| Mucoadhesion | Polymer interactions, hydration, tissue testing | Supports temporary contact mechanism |
| QbD and analytics | ICH principles, validation, dissolution modelling, stability and residual solvents | Supports development and data integrity |

## III. PEPTIC ULCER DISEASE AND CLINICAL CONTEXT

Peptic ulcer disease is associated primarily with H. pylori infection and NSAID or aspirin exposure, although smoking, stress and hypersecretory disorders can modify risk. Acid suppression supports healing, but cause-directed therapy remains necessary when infection or ulcerogenic medicines are involved [1-5].

A formulation intended for gastric drug delivery must therefore be judged first by pharmaceutical quality attributes. Claims about symptom relief, recurrence prevention, bleeding reduction or eradication success require clinical studies

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

and cannot be inferred from release profiles. This distinction is central to responsible development of a vonoprazan microballoon system.

Immediate-release vonoprazan represents an existing drug-delivery approach. A modified delivery system should preserve dose accuracy and early availability while reducing burst release and improving reproducibility. A slower release curve alone is not evidence of therapeutic benefit.

## IV. VONOPRAZAN FUMARATE AS ACTIVE DRUG

Vonoprazan is a potassium-competitive acid blocker that inhibits gastric H+/K+-ATPase without acid-catalysed activation. It accumulates in acidic secretory canaliculi and produces a sustained pharmacodynamic effect. The fumarate salt is the relevant pharmaceutical form for marketed products and formulation development [6-11].

The drug profile creates both opportunity and caution. Acid stability and potent pharmacodynamics support formulation investigation, but the existing sustained pharmacodynamic effect means that a controlled-release carrier must be justified by pharmaceutical performance rather than assumed clinical advantage.

Solubility and phase distribution are especially important for microballoons. Drug movement from organic droplets into the aqueous PVA phase can reduce entrapment, while poor compatibility may create crystals on the particle surface. Quantitative solubility studies should therefore precede final polymer and solvent selection.

*Table 2. Drug-related considerations for a vonoprazan microballoon system.*

| Drug feature | Development implication | Evidence boundary |
|---|---|---|
| Acid stability | Supports gastric formulation development | Does not establish superiority of retention |
| Potent acid suppression | Provides therapeutic rationale | Does not replace H. pylori-directed therapy |
| Basic amine and ionization | May affect solubility and compartmental accumulation | Requires quantitative solubility and release data |
| Fumarate salt | Defined solid-state form for development | Batch identity and stability must be confirmed |
| Drug interactions and safety | Need comparison with official product information | Modified release needs separate safety evaluation |

## V. GASTRO-RETENTIVE AND FLOATING SYSTEMS

Floating systems are designed to remain buoyant by maintaining apparent density lower than gastric fluid. Hollow microballoons use a polymeric shell and internal void to reduce density. The literature supports the feasibility of this structure, but also shows that buoyancy depends on wettability, porosity, polymer composition, solvent removal and mechanical robustness [20-25,30-33].

Physiology limits translation. Fed or fasted state, motility, fluid volume, posture and pyloric sieving influence gastric residence. Static floating tests are useful formulation screens, but direct in-vivo evidence is required before claiming prolonged human residence.

Multiple-unit microballoons may offer advantages over single-unit systems by distributing the dose and reducing all-or-none emptying. However, individual particles remain subject to emptying and shear, and excessive aggregation can defeat the multiparticulate concept.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2




*Figure 2. Literature-guided selection flow for gastro-retentive microballoons.*

## VI. MUCOADHESION AND POLYMER SELECTION

Mucoadhesion is a dynamic process involving wetting, hydration, intimate contact, polymer-chain mobility, interpenetration and secondary bonding. Theories of mucoadhesion provide a conceptual basis, but test conditions strongly affect measured values [26-29,46,47].

Carbopol, chitosan and HPMC are plausible candidates because they differ in charge, hydration and chain behaviour. Carbopol can provide strong hydrogen bonding and swelling, chitosan can contribute cationic interaction with mucus, and HPMC can modify hydration and release. Excessive polymer hydration may increase density, cause aggregation or slow terminal release.

Ex-vivo methods should report tissue source, anatomical region, procurement-to-test interval, storage, hydration, preload, contact time, motion or detachment rate and comparator. Without these details, a percentage adhesion value is difficult to compare across studies.

*Table 3. Mucoadhesive polymer options and interpretation cautions.*

| Polymer | Potential advantage | Key caution |
|---|---|---|
| Carbopol 934P | Strong hydration and hydrogen-bonding capacity | Excess swelling may increase density or alter release |
| Chitosan | Cationic interaction with mucus; film-forming tendency | Performance depends on deacetylation and pH |
| HPMC K4M/K15M | Hydration and release-modifying | May reduce buoyancy if hydration is |

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

| | | |
|---|---|---|
| | behaviour | excessive |
| Polymer blends | Balance adhesion, buoyancy and release | Requires mixture-specific optimization |

## VII. EMULSION SOLVENT DIFFUSION-EVAPORATION MICROBALLOONS

In this method, drug and shell polymers are dissolved or dispersed in an organic phase and added into an aqueous stabilizer phase. Droplet formation, solvent diffusion, evaporation and polymer precipitation create a shell and internal cavity. Process variables such as viscosity, addition rate, stirring speed, phase ratio, temperature and drying affect the final product [30-33].

The method is attractive for laboratory development because it can produce hollow particles without complex equipment. Its limitations include solvent selection, residual solvent control, scale sensitivity, variable size distribution and possible drug migration into the external phase.

Each manufacturing run should be supported by a complete batch record. A failed batch may be scientifically valuable because it reveals factor boundaries; excluding it without assignable cause can bias an optimization model.




*Figure 3. Mechanistic links between polymer hydration, buoyancy, mucoadhesion and release.*

## VIII. QUALITY-BY-DESIGN AND ANALYTICAL REQUIREMENTS

QbD translates product intent into measurable quality targets, critical quality attributes, material attributes, process parameters, risk assessment, designed experiments and a control strategy. For vonoprazan microballoons, CQAs include identity, assay, particle size, morphology, yield, drug loading, entrapment, buoyancy, mucoadhesion, release, residual solvent, moisture and stability [34-38].

Analytical methods must be suitable for the decisions they support. Specificity, accuracy, precision, linearity, range, robustness, filter compatibility and solution stability are required for assay and dissolution decisions. A high regression coefficient alone is not a validation result [43].

Dissolution modelling should be descriptive, not overstated. Higuchi and Korsmeyer-Peppas models can help compare release mechanisms, but model fit does not prove a unique mechanism without residual inspection, parameter plausibility and correct geometry assumptions [39-42].

*Table 4. QbD elements for vonoprazan microballoons.*

| QbD element | Application to microballoons | Documentation required |
|---|---|---|
| QTPP | Capsule-filled hollow multiparticulate with controlled release | Target profile and claim boundary |

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

| | | |
|---|---|---|
| CQAs | Assay, size, morphology, buoyancy, mucoadhesion, release, stability | Methods and acceptance logic |
| CMAs | Drug solid state, polymer grade, solvent quality, PVA characteristics | Supplier, grade, batch and CoA |
| CPPs | Stirring, addition rate, phase ratio, temperature, drying | Calibrated process record |
| Control strategy | Material, process, in-process and finished-product controls | Integrated checklist and change control |

## IX. STABILITY, RESIDUAL SOLVENTS AND SAFETY BOUNDARIES

Residual solvent control is a central safety requirement for solvent diffusion-evaporation products. The drying endpoint cannot be judged solely by appearance; solvent-specific testing should be performed when applicable. Solvent selection should balance pharmaceutical function and toxicological risk [38].

Stability studies should monitor appearance, aggregation, moisture, assay, degradation, buoyancy, mucoadhesion and dissolution. Short-term development stability can support formulation selection, but shelf life requires a suitable ICH-aligned data package [37].

Safety interpretation should remain proportional. Use of an approved drug substance does not make a novel carrier automatically safe, and a carrier with favourable in-vitro performance should not be described as clinically superior before comparative evidence exists.

## X. CRITICAL SYNTHESIS AND RESEARCH GAP

The literature supports the individual components of the concept: vonoprazan has strong acid-suppressing pharmacology, hollow microballoons can float, mucoadhesive polymers can interact temporarily with mucosa, and QbD can organize development. The unresolved gap is integration: the same formulation must simultaneously achieve acceptable yield, loading, hollow morphology, buoyancy, mucoadhesion, controlled release, residual solvent and stability.

The most important risk is overinterpretation. A static floating test is not human gastric retention; an ex-vivo adhesion value is not permanent attachment; and a slow release profile is not clinical benefit. The development pathway must therefore begin with pharmaceutical feasibility and proceed to in-vivo or clinical evaluation only after product quality is reproducible.

Future work should focus on authenticated batch-level experimental data, representative microscopy, validated assay and dissolution methods, residual solvent measurement, confirmation batches and direct in-vivo evaluation when justified. Data integrity should require full retention of raw observations, failed batches, calculation files and model diagnostics.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2




*Figure 4. Evidence domains and boundary of claims for the review.*

## XI. CONCLUSION

The literature supports a rational formulation-development pathway for vonoprazan fumarate gastro-retentive mucoadhesive microballoons. The concept is scientifically plausible when it is framed as a pharmaceutical platform requiring evidence of dose accuracy, buoyancy, temporary mucoadhesion, controlled release, residual-solvent control and stability. The literature does not justify unsupported claims of improved bioavailability, gastric residence or clinical superiority. A robust QbD and data-integrity framework is therefore essential for future experimental development.

## REFERENCES

**[1].** Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009;71(3):505-518.

**[2].** Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005;6(3):E372-E390.

**[3].** Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Vonoprazan versus lansoprazole for healing erosive oesophagitis: randomised clinical trial. Aliment Pharmacol Ther. 2016;43(2):240-251.

**[4].** Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release. 2006;111(1-2):1-18.

**[5].** Carvalho FC, Bruschi ML, Evangelista RC, Gremião MPD. Mucoadhesive drug delivery systems. Braz J Pharm Sci. 2010;46(1):1-17.

**[6].** Chakote VR, Dhembre GN, Rajguru JR, Joshi DA. In-Situ Gel for Nasal Drug Delivery. *International Journal of Development Research*. 2018;8(2):18763–18769.

**[7].** Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

**[8].** Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608-619.

**[9].** Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-133.

**[10].** DailyMed. VOQUEZNA (vonoprazan fumarate) tablets: full prescribing information. Bethesda (MD): US National Library of Medicine; updated 2025.

**[11].** Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249-257.

**[12].** Dhamale GR, Shinde PB, Rajguru JR. A Review: Gastroretentive Drug Delivery Systems. *International Journal of Pharmaceutical Sciences*. pp.1825–1840. doi:10.5281/zenodo.12818744.

**[13].** Doke R, Rajguru J, Vinchurkar K. Personalized Medicine Through AI-Driven Imaging. In: *Springer Nature*. doi:10.1007/978-3-032-02963-8_7.

**[14].** Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409-418.

**[15].** El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharm. 2001;220(1-2):13-21.

**[16].** Gadekar SN, Rajguru JR, Biyani KR. Review on Solid Dispersion for Suitable Drug. *World Journal of Pharmaceutical Sciences*. 2021;9(9):230–235.

**[17].** Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439-443.

**[18].** Gawai NM, Jadhav RR, Modak A, Sawarkar HS, Rajguru JR. Advancements in Nanogel Technology for Drug Delivery: Current Innovations and Future Perspectives. *African Journal of Biomedical Research*. 2024;27(3S):3200–3212. doi:10.53555/AJBR.v27i3S.2905.

**[19].** Gawari PB, Rajguru JR. Confronting the Nipah Virus: Critical Insights and Practical Recommendations. *International Journal of Creative Research Thoughts (IJCRT)*. 2026;14(2). ISSN: 2320-2882.

**[20].** Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.

**[21].** Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker. J Pharmacol Exp Ther. 2010;335(1):231-238.

**[22].** Ingole RD, Gawai NM, Rajguru JR. Nanoformulation of Vitamin D Derivatives and Metabolites. *African Journal of Biomedical Research*. 2024;27(4S). doi:10.53555/AJBR.v27i4S.4897.

**[23].** International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.

**[24].** International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. Geneva: ICH; 2023.

**[25].** International Council for Harmonisation. ICH Q3C(R8): Impurities: Guideline for Residual Solvents. Geneva: ICH; 2021.

**[26].** International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009.

**[27].** International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023.

**[28].** JRajguru R. Development and Validation of RP-HPLC and UV Spectrophotometric Absorptivity Method for Simultaneous Estimation of Cyclobenzaprine Hydrochloride and Aceclofenac in Pharmaceutical Dosage Form. *International Journal of Science & Engineering Development Research*. 2020;5(4):320–329.

**[29].** Jeevan Rajguru R. Magnetic and pH Sensitive Nanoparticles for Cancer Drug Delivery. *Asian Journal of Pharmaceutical Research and Development*. 2019;7(4).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

**[30].** Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636-648.

**[31].** JR.Rajguru Biomarkers and Diagnostics. *International Journal of Scientific Development and Research*. 2020;5(4).

**[32].** JR. Rajguru Development and Evaluation of Nasal Mucoadhesive In-Situ Gel Formulations of Carbamazepine Using In-Vitro, Ex-Vivo and In-Vivo Methods. *International Research Journal of Pharmacy and Medical Sciences*. 2018;1(6).

**[33].** Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033-1041.

**[34].** Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Preparation of multiple-unit hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics in vitro and floating behavior in vivo. J Control Release. 1991;16(3):279-290.

**[35].** Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci. 2011;11(6):748-764.

**[36].** Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.

**[37].** Kushwah P, Rajguru JR, Jain G, Patidar A, Tomar PS. A Review of Classic Cures for Contemporary Marvels: Unveiling the Medicinal Secrets of *Piper betle* Linn. Leaves and *Nyctanthes arbor-tristis*. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–D747.

**[38].** Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan versus lansoprazole for healing and maintenance of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61-71.

**[39].** Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613-624.

**[40].** Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and other natural polymers. Int J Pharm. 1992;78(1-3):43-48.

**[41].** Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for abbreviated new drug applications. AAPS J. 2008;10(2):268-276.

**[42].** Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm. 2016;510(1):144-158.

**[43].** Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724-1762.

**[44].** Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised phase 3 study. Gut. 2018;67(6):1042-1051.

**[45].** Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20(6):64-74.

**[46].** Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. Gut. 2016;65(9):1439-1446.

**[47].** Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018;115(3):219-224.

**[48].** Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334-344.

**[49].** Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate. Adv Ther. 2016;33(7):1140-1157.

**[50].** Pawar PP, Rajguru JR, Navghare AB, Shinde SP, Lokhande PB. An Overview of Implantable Drug Delivery Systems. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–F958.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

**[51].** Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv. 2011;18(2):97-110.

**[52].** Peppas NA, Buri PA. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Release. 1985;2:257-275.

**[53].** RRajguru J. Gene Therapy – Challenges & Success. *International Journal of Trend in Scientific Research and Development*. 2020;4(3).

**[54].** Rajguru JR, Gawari PB, Desai RS, Isal AA. Overview of Intrauterine Drug Delivery System. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–D316.

**[55].** Rajguru JR, Shirsat MK. Development of the Formulation and Evaluation of the Anti-Arthritic Activity of *Vitex negundo* Gel and Latex. *International Journal of Drug Delivery Technology*. 2023;13(1).

**[56].** Rajguru JR. A Review – Corona Virus (COVID-19). *International Journal of Science and Engineering Development Research*. 2020;5(4):1–6.

**[57].** Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers: are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther. 2018;9(7):63-72.

**[58].** Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomized open-label crossover study. Aliment Pharmacol Ther. 2015;42(6):719-730.

**[59].** Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2021;56:303-322.

**[60].** Shinde PB, Rajguru JR, Shinde SP, Humbe KA, Pawar PP. Nasal Routes of Drug Delivery: A Creative Approach. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)–E477.

**[61].** Shirsat MK. Rajguru JR, Development of the Formulation and Evaluation of the Anti-Inflammatory Activity of *Vitex negundo* Gel and Latex. *International Journal of Pharmaceutical Quality Assurance*. 2023;14(1).

**[62].** Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235-259.

**[63].** Sitaphale GR, Tathe PR, Laddha PR, Charhate KB, Rajguru JR. Phytochemical Screening, Isolation, and Characterization of Extract from Various Parts of *Phoenix sylvestris*. *African Journal of Biomedical Research*. 2024;27(3S):3368–3374. doi:10.53555/AJBR.v27i3S.2938.

**[64].** Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-1568.

**[65].** Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Development of hollow microspheres as floating controlled-release systems for cardiovascular drugs. Drug Dev Ind Pharm. 2001;27(6):507-515.

**[66].** Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of cimetidine: formulation, characterization and in vitro evaluation. Acta Pharm. 2005;55(3):277-285.

**[67].** Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006;3(2):217-233.

**[68].** Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Ther Adv Gastroenterol. 2018;11:1756283X17745776.

**[69].** Tathe PR, Laddha PR, Sitaphale GR, Charhate KB, Pimple UA, Jadhao YD, Alhat RM, Rajguru JR. Studies in Preparation and Evaluation of Nanoparticles for Controlled Drug Delivery of Peptide-Based Drugs. *African Journal of Biomedical Research*. 2024;27(3S):3179–3190. doi:10.53555/AJBR.v27i3S.2894.

**[70].** Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules. J Pharm Sci. 1994;83(1):18-24.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

**[71].** Wayal SR, Barke SA, Darekar SM, Jalindar AS, Gawai NM, Wankhede HR, Bathe RS, Rajguru JR. Development of Currant-Loaded Nanoparticles and Phytosomes for Enhanced Antioxidant Delivery. *International Journal of Environmental Sciences*. 2025;11(22S):4067–4071. doi:10.64252/p2tecx31.

**[72].** Wayal SR, Darekar SM, Jalindar AS, Motr PR, Gawai NM, Bodake PL, Barke SA, Dongare AB, Rajguru JR. Development of a Validated HPTLC Method for the Simultaneous Estimation of Curcumin and Berberine in Dashamoola Kvatha. *International Journal of Environmental Sciences*. doi:10.64252/kq9rtn45.

**[73].** Wayal SR, Rajguru JR, Bhise MR. A Systematic Review on the Effective Teaching Strategies and Methods for Cancer Patient Education. *Journal of Cancer Education*. 2025. doi:10.1007/s13187-025-02759-z.

**[74].** Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release. 1998;55(1):3-12.